Tracer library / [89Zr]Zr-DFO-girentuximab

[89Zr]Zr-DFO-girentuximab

Also written as [89Zr]Zr-DFO-girentuximab

Radionuclide: Zr-89 t½ 4704 min
Modality: PET
Production route: —
Stage: Clinical research
Syntheses indexed: 1

Bone metastases and bone lesions Brain metastases Breast cancer Gastrointestinal and colorectal cancer Tumour hypoxia Other radioligand therapy Bladder cancer

What it is

Compound class: Radiolabeled monoclonal antibody (anti-CA-IX chimeric antibody, DFO-conjugated)
Target / mechanism: Targets Carbonic Anhydrase IX (CA-IX) antigen PMID 41174094
Clinical application: PET/CT imaging of CA-IX-expressing tumors PMID 41174094
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	87	>95%	H3DFOSq-girentuximab	41631002 2026 Gastro Hep Adv [89Zr]ZrIV in 0.05 M oxalic acid (250 μL, 165 MBq, Austin Health) was neutralized with sodium acetate buffer - combined to a given 143 MBq (87% isolated radiochemical yeild) in 3 mL with >95% radiochemical purity

Need this precursor?We can point you to suppliers for [89Zr]Zr-DFO-girentuximab, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impurities

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [89Zr]Zr-DFO-girentuximab.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with Zr-89. Stage set/updated at stage 23 from PMID 40227816: 'Additionally, a clinical proof-of-concept study, PERTINENCE, that used [89Zr]Zr-girentuximab for PET/CT imaging in bladder cancer patients was conducted.'. | Stage 28: added indication(s) onc-bladder from consolidated missing-rubric review. | Stage 30 (2026-09-18): Stage was 'clinical proof-of-concept / prospective pilot study'; normalised to 'Clinical research', original wording kept here.